Aimmune secures licence to Xencor’s XmA 7195 to develop food allergy treatments
Under an exclusive worldwide licence, Aimmune will develop and commercialise the XmAb 7195, an investigational humanised monoclonal antibody. Xencor president and CEO Dr Bassil Dahiyat said: “Aimmune’s focus,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.